GSK plc (the 'Company') Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Di	Hal Barron	
b)	Position/status	N	on-Executive Director	
c)	Initial notification/ amendment	Ini	tial notification	
2.		Is of the issuer, emission allowance market participant, auction platform, oneer or auction monitor		
a)	Name	G	SK plc	
b)	LEI	54	93000HZTVUYLO1D79	3
3.	Details of the transaction(s): section to be repeated for (i) each type of instrumen (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument		merican Depositary Sha IN: US37733W2044	ares ('ADSs')
b)	Nature of the transaction	Sı		DSs within Dr Barron's GSK Executive an account following the reinvestment of
c)	Price(s) and volume(s))	Price(s)	Volume(s)
			36.6400	3,269.946
d)	Aggregated information	N/	A (single transaction)	
	Aggregated volume Price			
2)	Date of the	20	25-02-21	
e)	transaction			

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr Hal Barron	
b)	Position/status	Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		

a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1E)793
3.		saction; (iii) each dat	repeated for (i) each type of instrument; e; and (iv) each place where
a)	Description of the financial instrument	American Depositary S ISIN: US37733W2044	Shares ('ADSs')
b)	Nature of the transaction	Acquisition of ADSs w following the reinvestm	ithin Dr Barron's GSK 401(k) plan account ent of dividends
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		36.6400	83
d)	Aggregated information	N/A (single transactior)
	Aggregated volume Price		
e)	Date of the transaction	2025-02-21	
f)	Place of the transaction	New York Stock Exch	ange (XNYS)

	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	(ii) each type of tran transaction(s) has be		
3. a)	(ii) each type of tran transaction(s) has be	saction; (iii) each date; and (iv) each place where	
a)	(ii) each type of tran transaction(s) has be Description of the	saction; (iii) each date; and (iv) each place where een conducted American Depositary Shares ('ADSs')	
	(ii) each type of tran transaction(s) has be Description of the financial instrument Nature of the	saction; (iii) each date; and (iv) each place where een conducted American Depositary Shares ('ADSs') ISIN: US37733W2044 Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment dividends	
a) b)	(ii) each type of tran transaction(s) has be Description of the financial instrument Nature of the transaction	saction; (iii) each date; and (iv) each place where een conducted American Depositary Shares ('ADSs') ISIN: US37733W2044 Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment dividends	

	Aggregated volume Price	
e)	Date of the transaction	2025-02-21
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group Genera	Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.	Details of the transa (ii) each type of tran transaction(s) has be	saction; (iii) each date	epeated for (i) each type of instrument; ; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ½ ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction	Sale of 10,400 Ordinary	Shares
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.5541	10,400
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
		1	
e)	Date of the transaction	2025-02-25	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
2)	Nama	Cok nh	

aj	เทศเทษ	
b)	LEI	5493000HZTVUYLO1D793
3.		ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where sen conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Gift of ordinary shares to family member for nil consideration
c)	Price(s) and volume(s)	Price(s) Volume(s) £0.00 123,700
d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2025-02-21
f)	Place of the transaction	London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

DSHSEMFIMEISELE